natgillin/translations-raw huggingface dataset:
placing a grippable cap onto the grip component such that said tubular body fits within a cavity of said grippable cap so that the grippable cap backs up the grip component, whereby said at least one radial inward projection can engage the shield for removal purposes when the cap is moved from the housing. 
omogućavanja elastičnosti predmetnog cjevastog tijela da izazove automatsko vraćanje predmetnog cjevastog tijela prema neutralnom položaju oko štitnika u predmetnom podsklopu; i podstavljanja zahvatne kapice (30) na komponentu držača predmetnog podsklopa tako da se predmetno cjevasto tijelo uklopi unutar šupljine (140) predmetne zahvatne kapice tako da zahvatna kapica podupire komponentu držača, naznačeno time, što najmanje jedno radijalno izbočenje prema unutra može zahvatiti štitnik u svrhe uklanjanja kada se kapica ukloni iz kućišta.
The method of claim 14 wherein said osmoprotective protein is a proline or a glycine-betaine, a taurine transporter, a glycine betaine-Y-aminobutyric acid transporter, a sodium-myo-inositol cotransporter, a heat shock protein, an aquaporin, an aldose reductase, or a neuropathy target esterase (NTE). 
Postupak u skladu s patentnim zahtjevom 14, naznačen time, da je spomenuti osmoprotektivni protein prolin ili glicin betain, taurinski transporter, transporter glicin betaina-y-transporter aminobutirične kiseline, natrijev-mio- inozitolski kotransporter, protein toplinskog šoka, aquaporin, aldoza-reduktaza ili neuropatska ciljna esteraza (NTE).
An oral suspension comprising (a) an antibiotic composition which comprises coated micropellets and optionally one or more excipients, (b) additional excipients, and (c) a solvent, wherein said coated micropellets comprise 
Oralna suspenzija, naznačena time, da sadrži (a) antibiotski pripravak koji sadrži obložene mikropelete 1 po izboru jedno ili više pomoćnih sredstava, (b) dodatna pomoćna sredstva, 1 (c) otapalo, pri čemu mikropelete sadrže
28 . Cell Proliferation Analysis Transfection of cells with ISC-468-specific siRNA duplexes resulted in distinct impairment of (A) chemotaxis, (B) chemokinesis, and (C) invasion compared to control cells. 
(d) nukleinska kiselina koja je najmanje 95% identična sa nukleinskom kiselinom pod (a), (b) ili (c) za uporabu u liječenju, prevenciji, dijagnostificiranju ili praćenju bolesti kancera naznačene ekspresijom proteina ili polipeptida.
the Eosin-Y is present in amounts sufficient to result in concentrations of about 27 µM under staining conditions. 
Eozin-Y je prisutno u dovoljnoj količini da se dobiju koncentracije od oko 27 uM u uvjetima bojenja.
The compound of claim 1, wherein L is a polyethylene glycol linker. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da L je polietilen glikol linker.
In the method, the method further comprises the step of assigning to the subject the likelihood of having an adverse reaction to telomerase inhibitor treatment. 
Postupak prema zahtjevu 1, pri čemu postupak nadalje obuhvaća korak dodjeljivanja subjektu vjerojatnosti razvitka nuspojave na liječenje terapijom inhibicije telomeraze.
A method according to any of claims 1 to 11, wherein the melt is provided on to the periphery of the first rotor at a temperature of 1450 to 1575ºC, preferably 1480 to 1550ºC. 
Postupak sukladno bilo kojem od patentnih zahtjeva 1 do 11, pri čemu je rastaljeni material postavljen na periferiji prvog rotora na temperaturi od 1450 do 1575"C, preporučljivo 1480 do 1550%C.
coupling a compound of formula 2 (X = Cl, Br) with suitable boronic acids or boronic acid esters of formula 3 wherein R' is hydrogen or lower alkyl, to afford compounds of formula I wherein R is hydrogen, and, if desired, converting the obtained compound into pharmaceutically acceptable acid addition salts or into a compound of formula I, wherein R is tritium,; or 
spajanje spoja formule 2 (X = Cl, Br) [image] s prikladnim bornim kiselinama ili esterima borne kiseline formule 3 [image] pri čemu je R’ vodik ili niži alkil, kako bi se stvorili spojevi formule I [image] pri čemu je R vodik, te ako je poželjno, pretvaranje dobivenog spoja u farmaceutski prihvatljive kiselinske adicijske soli ili u spoj formule I, pri čemu je R tricij; ili
The system of claim 5 wherein the electric heater has a maximum dimension perpendicular to the electric heater's length that varies. 
Sustav (10) prema zahtjevu 5, pri čemu električni grijač (14) ima vertikalnu dimenziju u odnosu na njegovu dužinu, koja varira.
The jack system of claim 1, wherein the seating means comprises a concave appendage attached to, or formed in, a central region of each of the respective arms. 
Sustav dizalica (10, 100) sukladno zahtjevu 2, naznačen time da sredstvo sjedišta (26, 126) sadrži konkavni dodatak koji je pričvršćen na, ili je oblikovan u, središnjem području svakog odnosnog kraka (20,120).
In this manner, the neck ring arms 14 that are carried by the ball spline nuts 42,43, are moved along the axis 46 toward each other to a closed position and away from each other to an open position. 
Na ovaj se način hvataljke kalupa (14), koje nose kuglasto-klinaste matice (42), (43), pomiču duž osi (46) jedna prema drugoj za zatvaranje, odnosno jedna od druge za otvaranje.
A method for predicting a therapeutic effect of chemotherapy that uses an antitumor agent comprising a,a,a-trifluorothymidine and 5-chloro-6-(1-(2-iminopyrrolidinyl)methyl)uracil hydrochloride at a molar ratio of 1:0.5 on a colorectal cancer patient, the method comprising the steps of: 
Postupak predviđanja terapijskog učinka kemoterapije u kojoj se upotrebljava protutumorsko sredstvo koje sadrži 0,0,a-trifluortimidin i 5-klor-6-(1-(2-iminoirolidinil)metiljuracil-hidroklorid u molarnom omjeru od 1:0.5 na pacijentu s kolorektalnim rakom, naznačen time što se postupak sastoji u koracima:
The heterodimeric, conditionally active CAR of claim 1, wherein the intracellular signaling domain is a CD3-zeta intracellular signaling domain or a ZAP-70 intracellular signaling domain. 
Heterodimerni, uvjetno aktivni CAR u skladu s patentnim zahtjevom 1, naznačen time, da unutarstanična signalna domena je unutarstanična CD3-zeta signalna domena ili unutarstanična ZAP-70 signalna domena.
The combined HCI salt, which contained about 70% cis-racemate and 30% trans-racemate of N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine hydrochloride, was dissolved in hot methanol (2 1. 
Spojena HCI sol, koja je sadržavala oko 70% cis-racemata i 30% trans-racemata N-metil-4-(3,4- diklorofenil)-1,2,3,4-tetrahidro-1-naftalinamin klorhidrata, otopi se u vrućem metanolu (2 1.
The CD3-binding molecule of any one of claims 1-2, wherein said CD3-specific VH domain is h-mab2 VH-8 having the amino acid sequence of SEQ ID No:50, or h-mab2 VH-4 having the amino acid sequence of SEQ ID No:42. 
CD3-vezujuća molekula prema bilo kojem od patentnih zahtjeva 1-2, naznačena time što navedena CD3-specifična VH domena je h-mab2 VH-8 koja ima aminokiselinsku sekvencu SEQ ID No:50, ili h-mab2 VH-4 koji ima aminokiselinsku sekvencu SEQ ID No:42.
A method for determining an amount of biologically active Clostridium botulinum neurotoxin (BoNT) in a preparation, comprising the steps of: contacting a human induced pluripotent stem (hiPS) derived neuronal cell with a sample of a preparation comprising biologically active BoNT; and 
Postupak određivanja količine biološki aktivnog BoNT u pripravku koji sadrži biološki aktivni BoNT, naznačen time što se navedeni postupak sastoji u koracima: (a) stavljanja u kontakt živčane stanice nastale 1z stanice hiPS s uzorkom pripravka koji sadrži biološki aktivni BoNT;1
A combination suitable for use in the treatment of cancer comprising a pharmaceutically acceptable composition as claimed in claim 11 and another anti-tumour agent. 
Kombinacija pogodna za upotrebu u liječenju raka naznačena time da sadrži farmaceutski prihvatljiv pripravak prema zahtjevu 11 i drugo sredstvo protiv tumora
Composition according to any one of the preceding claims, wherein the solids content of the composition is at least 10 wt.%, preferably at least 20 wt.%, most preferably at least 30 wt.%. 
Pripravak prema bilo kojem od prethodnih zahtjeva, naznačen time, što sadržaj čvrste tvari u pripravku je najmanje 10 mas.%, poželjno najmanje 20 mas.%, najpoželjnije najmanje 30 mas.%.
preferably in a patient at least partially resistant to treatment with a given chemotherapeutic drug or with radiotherapy, or 
namijenjena upotrebi u skladu s patentnim zahtjevom 4, kod pacijenta koji je u najmanju ruku djelomično otporan na liječenje danim kemoterapijskim lijekom ili radioterapijom, ili
reacting an intermediate of formula (VIII) with lithium aluminium hydride in a suitable solvent, to obtain compounds of formula (I) wherein s is 1, herein referred to as compounds of formula (I-d) with the variables as defined in claim 1; 
(I-c) sa varijablama kako je definirano u zahtjevu I; e) reakciju intermedijera prema formuli (VIII) sa litij aluminij hidridom u prikladnom otapalu, da se dobiju spojevi prema formuli (1) pri čemu s je 1, ovdje se nazivaju spojevi formule (I-d)
blending said granulated mixture with at least one bioadhesive polymer, at least one polymer that provides a sustained release and at least one compression agent; and compressing the blended mixture obtained in b). 
€) miješanje navedenih primarnih granula sa najmanje jednim bioadhezivnim polimerom i najmanje jednim polimerom za produženo oslobađanje i najmanje jednim sredstvom za prešanje; i f) prešanje navedene smjese u e).
An engineered fuel feedstock, comprising at least one component derived from a processed MSW waste stream, the feedstock comprising: 
Modificirano zamjensko gorivo, koje sadržava najmanje jednu komponentu koja je dobivena iz procesiranog komunalnog otpada, a sirovina sadržava:
The components A) and B) and, if desired, C) can be formulated jointly, but also separately, and/or applied to the plants, their environment and/or seeds jointly or separately. 
Komponente A) 1 B) i, prema potrebi, C) mogu biti formulirane zajedno, ali također odvojeno, i/ili mogu se primjenjivati na biljke, njihovu životnu sredinu i/ili sjeme, zajedno ili odvojeno.
A method according to claim 17, comprising monitoring the maturity degree of the bioredegradation of the sludge by measuring carbon dioxide emissions of the sludge. 
Metoda u skladu s patentnim zahtjevom 15, karakterizirana praćenjem stupnja zrelosti biodegradacije mulja mjerenjem emisije ugljikovog dioksida iz mulja.
Particularly, said additional amino acid mutation is an amino acid substitution replacing a threonine residue by an alanine residue. 
Imunokonjugat prema zahtjevu 5, naznačen time, da navedena aminokiselinska mutacija je aminokiselinska supstitucija na položaju P329 (EU numeracija).
The antibody, immunoconjugate, pharmaceutical composition, bispecific or multispecific molecule or expression vector for use according to claim 25, wherein the disease is multiple myeloma. 
Protutijelo, imunokonjugat, farmaceutski pripravak, bispecifična ili multispecifična molekula za uporabu u skladu s patentnim zahtjevom 17, naznačeno time da je bolest multipli mijelom.
The process as claimed in claim 1, wherein the temperature used in Step (iii) is 75 °C to 80 °C. 
Postupak sukladno patentnom zahtjevu 1, naznačeno time, da je temperatura korištena u Koraku (iii) 75 *C do 80 "€.
The computer cluster arrangement according to one of the preceding claims, wherein each computation node (CN) comprises at least one of a group of components, said group comprising: a multi-core processor, a cluster, a computer, a workstation and a multi-purpose processor. 
Način raspoređivanja računalnog klastera u skladu s jednim od prethodnih patentnih zahtjeva, naznačen time, da svaki računalni čvor (CN) sadržava najmanje jednu od skupina komponenti, pri čemu navedena skupina sadržava: višejezgreni procesor, klaster, računalo, radnu stanicu i višenamjenski procesor.
The depth of the insertion of the device is individualised by stopping further insertion once resistance is felt at reaching the deepest part of the related cavity. 
Dubina umetanja ove naprave je individualna i daljnje umetanje se zaustavlja kada se jednom osjeti otpor pri dostizanju najdubljeg dijela odgovarajuće šupljine.
The sealing device of clause 22, wherein said annular metal body seal element has a coating of dielectric material. 
Izolacijski sustav prema zahtjevu 1, naznačen time, da spomenuti prstenasti metalni zaptivni element (52) ima oblogu od dielektričnog materijala.
Composition according to claim 1 or 2, wherein the bioadhesive material has a weight average molecular weight of at least 10,000 Daltons, preferably at least 50,000 Daltons, more preferably at least 100,000 Daltons, still more preferably at least 1,000,000 Daltons, and most preferably from 1,000,000 to 10,000,000 Daltons. 
Pripravak u skladu s patentnim zahtjevom 1 ili 2, naznačen time,da bioljepljivi materijal ima težinsko sredstvo prosječne molekularne mase od najmanje 10 000 Daltona, poželjno najmanje 50 000 Daltona, poželjnije najmanje 100 000 Daltona, još više poželjno najmanje 1 000 000 Daltona, te najpoželjnije od 1 000 000 do 10 000 000 Daltona.
o Homogenize membranes briefly until in suspension using a POLYTRON PT3100 (probe PT-DA 3007/2 at setting of 7000 rpm). 
* - Homogeniziraj membrane kratko do suspenzije uporabom POLYTRON PT 3100 (proba PT-DA 3007/2 namještanjem 7000 okr./min).
Desirably the organophosphate or carbamate composition is left in contact with the hair for 15 minutes to 12 hours, especially 20 minutes to 4 hours, more preferably 30 minutes to 3 hours, most preferably about 2 hours. 
Organofosfat, karbamat, piretroid ili piretrin prema bilo kojem od zahtjeva 1 do 7 pri čemu izlaganje sredstvima protiv morskih uši traje u razdoblju od 10 do 100 minuta, i prvo 1 drugo sredstvo protiv morskih uši su vremenski raspoređeni u razmacima od 15 minuta do 4 sata.
Sterile solutions can also be administered intravenously. 
Sterilne otopine također se mogu primijeniti intravenski.
The suspended samples were heated at 95° C. for 5 minutes and subjected to SDS-PAGE on a 4–12% gel, followed by Western blot analysis using rabbit polyclonal anti-human GSTπ antibody followed by IRDye 800 conjugated, affinity purified goat anti-rabbit IgG antibody. 
Suspendirani uzorci zagrijavani su kod 95% C 5 minuta i podvrgnuti SDS-PAGE na 4-12% gelu, praćeni Western blot analizom uz korištenje zečjeg poliklonalnog antihumanog GSTr antitijela praćenog pomoću IRDye800 konjugiran, srodno pročišćeno koza anti-zec IgG antitijelo.
In all methods according to the invention it is preferred that the trans-(-)-A9-tetrahydrocannabinol is present in the first composition in an amount from 0.75 to 1.25 molar equivalents, preferably from 0.9 to 1.1 molar equivalents, more preferably from 0.95 to 1.05 molar equivalents and even more preferably of 1 molar equivalent per molar equivalent of trans-(+)-A9-tetrahydrocannabinol. 
Postupak prema zahtjevima 1 do 4, naznačen time da je trans-(-)-A*-tetrahidrokanabinol prisutan u prvom sastavu u količini od oko 0.75 do oko 1.25 molarnih ekvivalenata, poželjno od oko 0.9 do oko 1.1 molarnih ekvivalenata, još poželjnije od oko 0.95 do oko 1.05 molarnih ekvivalenata i čak još poželjnije oko 1 molarni ekvivalent po molarnom ekvivalentu trans-(+)-A-tetrahidrokanabinola.
A pipe clamp as claimed in claim 11, wherein in a first position of a coupling the clamping elements partially fill the further recess for clamping a pipe with a first diameter to a wire of the mesh reinforcement. 
Stezaljka za cijev prema Zahtjevu 8, gdje u prvom položaju spojnice (33) stezni elementi (35) djelomično ispunjavaju dodatno ulegnuće (34) radi stezanja cijevi prvog dijametra sa žicom armaturne mreže.
Examples of such dosage units are capsules, tablets, powders, granules or a suspension, with conventional additives such as lactose, mannitol, com starch or potato starch; with binders such as crystalline cellulose, cellulose derivatives, acacia, corn starch or gelatins; with disintegrators such as com starch, potato starch or sodium carboxymethyl-cellulose; and with lubricants such as talc or magnesium stearate. 
Primjeri takvih dozirnih oblika su kapsule, tablete, prašci, granule ili suspenzija, uz uobičajene aditive poput laktoze, manitola, kukuruznog škroba ili krumpirovog škroba; s vezivima poput kristalinične celuloze, derivata celuloze, akacije, kukuruzng škroba ili želatine; sa sredstvima za raspadanje poput kukuruznog škroba, krumpirovog škroba ili natrij karboksimetil celuloze; sa lubrikantima poput talka i magnezij stearata.
A composition comprising a suspension which comprises an admixture of a hydrophobic medium and a solid form wherein the solid form comprises a therapeutically effective amount of a therapeutic agent and at least one salt of a medium chain fatty acid, and wherein the medium chain fatty acid salt is present in the composition at an amount of 10% or more by weight, wherein the therapeutic agent is a polypeptide. 
Pripravak koji sadrži suspenziju koja sadrži smjesu hidrofobnog medija i kruti oblik pri čemu kruti oblik sadrži terapeutski učinkovitu količinu terapijskog sredstva i barem jednu sol masne kiseline srednjeg lanca, te pri je čemu sol masne kiseline srednjeg lanca prisutna u pripravku u količini od 10 masenih % ili više, naznačen time da terapijsko sredstvo je oktreotid.
The composition for use according to any one of claims 1-9, wherein said composition is a reconstituted lyophilized composition. 
Sastav za upotrebu prema bilo kojem od patentnih zahtjeva 1-9, pri čemu je navedeni sastav rekonstruirani liofilizirani sastav.
reacting a compound of formula (XV-S) with the compound of formula (XVII-S); in the presence of a Ni or Pd catalyst; in an organic solvent to yield the corresponding compound of formula (XVIII-S). 
d reagiranje spoja formule (XV-S) sa spojem formule (XVII-S); u prisutnosti Ni ili Pd katalizatora; u organskom otapalu da kako bi se dobio odgovarajući spoj formule (XCVIII-S).
1 to 8 relate to a process for transporting fluids such as, for example, natural gas, oil or water, and an underwater vehicle for effecting this process, according to a particular embodiment of the present invention. 
Hraste & Partneri odvjetničko društvo, 10000 Zagreb, HR (54) Naziv izuma: POSTUPAK TRANSPORTIRANJA EKSTRAKCIJSKIH FLUIDA, POPUT PRIMJERICE ZEMNOG PLINA, SIROVE NAFTE ILI VODE, | PODVODNO VOZILO ZA PROVOĐENJE TAKVOG
A combination comprising a therapeutically effective amount of a compound according to any one of embodiments 1 to 21 or a pharmaceutically acceptable salt thereof and one or more therapeutically active co-agents. 
7. < Kombinacija, naznačena time, da obuhvaća spoj prema bilo kojem od zahtjeva 1 do 5 ili njegovu farmaceutski prihvatljivu sol te jedno ili više dodatnih terapeutski sudjelatnih sredstava.
Method according to claim 1 or 2, wherein reaction (N-reac) is done in a solvent (N-solv); solvent (N-solv) is selected from the group consisting of water, tert-butanol, isopropanol, acetonitrile, propionitrile, THF, methyl-THF, NMP, dioxane, 1,2-dimethoxyethane, dichloromethane, 1,2-dichloroethane, chloroform, toluene, benzene, chlorobenzene, hexane, cyclohexane, ethyl acetate, acetic acid, formic acid, trifluoroacetic acid and mixtures thereof. 
Postupak prema zahtjevu 1 ili 2, naznačen time da se reakcija (N-reak.) provodi u otapalu (N-otop.); otapalo (N-otap.) je izabrano iz skupine koja se sastoji od vode, terc-butanola, izopropanola, acetonitrila, propionitrila, THF, metil-THF, NMP, dioksana, 1,2-dimetoksietana, diklormetana, 1,2-dikloretana, kloroforma, toluola, benzola, klorbenzola, heksana, cikloheksana, etilnog estera octene kiseline, octene kiseline, mravlje kiseline, trifluoroctene kiseline i njihovih mješavina.
Some multi dose inhalers have disposable drug containers that can be replaced after the prescribed number of doses has been taken (e. g. WO 97/000703). 
Neki inhalatori za više različitih doza imaju jednokratne spremnike za lijek koji se mogu zamijeniti nakon davanja propisanog broja doza (npr. WO 97/000703).
reducing Compound 21 to produce Compound 26: 
(a) redukciji Spoja 21 kako bi se dobilo Spoj 26:
performing prediction using at least one prediction unit to generate a predictor, and reconstructing the coding unit by using the residuals and the predictor, and 
Uređaj za kodiranje slike, te uređaj sadrži: memoriju koja pohranjuje tok bitova; i najmanje jedan procesor konfiguriran za:
a 3- to 8-membered monocyclic non-aromatic heterocyclic group optionally substituted by 1 to 3 substituents selected from 
3-člana do 8-člana monociklička nearomatska heterociklička skupina opcionalno supstituirana s 1 do 3 supstituenta odabrana od:
means for feeding the filtrate from said secondary treatment unit to said tertiary treatment unit. 
- > sredstvo za dopremu filtrata iz navedene jedinice za sekundarnu obradu u navedenu jedinicu za tercijarnu obradu.
R3b represents hydrogen or hydroxyl; provided that if R3a represents —NR10R11, then R3b represents hydrogen; or R3a and R3b are taken together to form ═O, to form ═NR10, to form cyclopropyl together with the carbon atom to which they are attached, to form ═CH—C0-4alkyl substituted with R3c, or to form 
b predstavlja vodik ili hidroksil; pod uvjetom da ako R3a predstavlja -NR10R11, tada R3b predstavlja vodik; ili R3a i R3b su uzeti skupa kako bi tvorili =O, kako bi tvorili =NR10, kako bi tvorili ciklopropil skupa s atomom ugljika na kojeg su vezani, kako bi tvorili=CH-C0-4alkil supstituiran s
In a more preferred embodiment, the present invention provides an anti- N3pGlu AB monoclonal antibody or antigen-binding fragment thereof for use in the prevention of Alzheimer's disease. In a further aspect, the present invention provides a use of an anti- N3pGlu AB monoclonal antibody or antigen-binding fragment thereof, in the manufacture of a medicament for the treatment of a condition selected from a group consisting of clinical or pre-clinical Alzheimer's disease, prodromal Alzheimer's disease, Down's syndrome, and clinical or pre-clinical CAA. 
Ljudsko modificirano protutijelo, ili njegov antigenski vežući fragment, u skladu s patentnim zahtjevom 1 ili farmaceutski pripravak u skladu s patentnim zahtjevom 2, naznačeno time što je namijenjeno upotrebi u liječenju stanja koje se bira iz skupine koju čine klinička ili pretklinička Alzheimerova bolest, prodromalna Alzheimerova bolest, Down sindrom, te klinička ili pretklinička cerebralna amiloidna angiopatija (CAA), koja se sastoji u primjeni na čovjeku kojem je to potrebno ljudskog modificiranog protutijela u skladu s patentnim zahtjevom 1.
The composition of any one of claims 1 to 5, wherein the polypeptide has the sequence as set forth in SEQ ID NO: 2 or SEQ ID NO: 4. 
Sastav iz bilo kojeg od patentnih zahtjeva 1 do 5, pri čemu polipeptid ima slijed kako je navedeno u SEQ ID NO:2 1li SEQ ID NOÂ«4.
the contents of the database system are used to determine the likely future location specific network needs, such that this information together with the characteristics of the new small cell are used to determine the placement co-ordinates of the new small cell, 
sadržaj sustava baze podataka upotrebljava se za određivanje moguće buduće lokacije koju specifična mreža treba zajedno s obilježjima nove male stanice,
The use of claim 1 or 2, wherein the nucleosidic component is a nucleic acid molecule comprising at least one modified building block. 
Uporaba u skladu s patentnim zahtjevima 1 ili 2, pri čemu je nukleozidna komponenta nukleinska kiselina koja sadrži najmanje jedan modificiran gradbeni blok.
Deposition No. Date of Deposit 
Datum podnošenja zahtjeva u HR:
The preferred assay method for measuring SDS levels is a spectrophotometric assay based on reaction with acridine orange, as described in more detail in the examples and in ref. 35. 
Preferirana analitička metoda za mjerenje razina SDS je spektrofotometrijska analiza bazirana na reakciji s akridin oranž bojilom, kako je detaljnije opisano u primjerima i u ref.